Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: Tolerance and efficacy
- François, Eric
- Azria, David
- Gourgou-Bourgade, Sophie
- Jarlier, Marta
- Martel-Laffay, Isabelle
- Hennequin, Christophe
- Etienne, Pierre-Luc
- Vendrely, Véronique
- Seitz, Jean-François
- Conroy, Thierry
- Juzyna, Beata
- Gérard, Jean-Pierre
DOIAbstract
International audienceBACKGROUND:Rectal cancer predominantly affects the elderly. Unfortunately, this age category is under-represented in clinical trials because clinicians are loath to include patients with a high risk of comorbidity.PATIENTS AND METHODS:An exploratory analysis of the ACCORD12/PRODIGE 2 phase III trial was carried out to retrospectively compare the benefit of neoadjuvant chemotherapy between the elderly (≥70 years; n=142) and younger patients (<70 years; n=442), this analysis was not preplanned in the study protocol. Patients with histologically confirmed resectable stage T3 or T4 rectal adenocarcinoma were eligible with an age limit of 80 years.RESULTS:Overall, the two age categories did not statistically differ in terms...
Add to ORKG